CERAMED is developing CeraDOSE®, the first dynamic blood-based biomarker test for accelerating recovery in patients with treatment-resistant depression. In partnership with leading French and German medical institutions (AP-HP, UK Erlangen, FU Berlin), we’re transforming months of trial-and-error into rapid, personalized care pathways.

For the ~50% of patients who don’t respond to their first antidepressant, CeraDOSE® offers hope through measurable biological insights. Our patented ceramide biomarkers—analyzed via standardized LC-MS/MS and interpreted by proprietary Model Factory algorithms—provide actionable guidance within a few days, enabling clinicians to:
• Accelerate patient recovery by identifying those who need dose optimization versus treatment change.
• Reduce time to remission from months to weeks for treatment-resistant patients.
• Prevent clinical deterioration through early identification of non-responders.
• Enable confident discharge decisions based on biological markers of treatment response.
• Predict and prevent relapses through longitudinal monitoring, supporting sustained recovery.

Our technology empowers medical teams with biological insights that complement and enhance clinical expertise—providing the missing piece for personalized depression care. Our SaaS platform enables continuous patient monitoring and proactive intervention, transforming reactive care into preventive medicine.

After 60 years lacking reliable psychiatric biomarkers, we're contributing to give clinicians actionable biomarkers they need to guide treatment decisions—reducing patient suffering, accelerating recovery, and restoring hope for those facing treatment-resistant depression.

With 3 patents filed, an assay method validated across 473+ patients, and CE marking planned for 2027, CERAMED is bringing precision care to the market for the millions of patients suffering from major depressive disorders.